Dachaigh › Ailseachadh nan Sgamhan › Oklahoma › Oklahoma City
Sgrùdaidhean clionaigeach Ailseachadh nan Sgamhan ann an Oklahoma City, OK
Tha 19 sgrùdaidhean airson Ailseachadh nan Sgamhan a’ lorg phàirtichean aig làraichean ann agus timcheall air Oklahoma City (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
The Vanguard Study: Testing a New Way to Screen for Cancer
A’ fastadhFàilte do shaor-thoilich fhallain
- University of Oklahoma Health Sciences Center, Oklahoma City
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
A’ fastadhÌre 3
- Mercy Hospital Oklahoma City, Oklahoma City
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
A’ fastadhÌre 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
- Integris Cancer Institute of Oklahoma, Oklahoma City
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
A’ fastadhÌre 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Cancer Institute of Oklahoma, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A’ fastadhÌre 1/2
- University of Oklahoma, Oklahoma City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Mercy Hospital Oklahoma City, Oklahoma City
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
A’ fastadhÌre 3
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
A’ fastadhÌre 3
- Hightower Clinical, LLC ( Site 0084), Oklahoma City
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
A’ fastadhÌre 2/3
- INTEGRIS Cancer Institute of Oklahoma, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
A’ fastadhÌre 1/2
- University of Oklahoma, Oklahoma City
Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Site 101, Oklahoma City
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
A’ fastadhÌre 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
A’ fastadhÌre 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
A’ fastadhÌre 1
- Xencor Investigative Site, Oklahoma City
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
A’ fastadhÌre 1/2
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
A’ fastadhÌre 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
A’ fastadhÌre 2/3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Southwest Medical Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
A’ fastadhÌre 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
A’ fastadhSgrùdadh amharc
- Hightower Clinical, Oklahoma City
Sgrùdaidhean Ailseachadh nan Sgamhan ann am bailtean eile
- Houston, TX78 sgrùdaidhean
- Boston, MA62 sgrùdaidhean
- New York City, NY60 sgrùdaidhean
- Los Angeles, CA45 sgrùdaidhean
- Arlington, VA41 sgrùdaidhean
- Washington, DC41 sgrùdaidhean
- Chicago, IL41 sgrùdaidhean
- Baltimore, MD40 sgrùdaidhean
- Nashville, TN40 sgrùdaidhean
- St. Louis, MO39 sgrùdaidhean
- Columbus, OH37 sgrùdaidhean
- Philadelphia, PA36 sgrùdaidhean
Sgrùdaidhean eile ann an Oklahoma City
- Aillse Sgamhain Neo-chealla-beag28 sgrùdaidhean
- Cancer Ovarian28 sgrùdaidhean
- Ailse Endometrial25 sgrùdaidhean
- Aillse colorectal22 sgrùdaidhean
- Aillse Prostata21 sgrùdaidhean
- Aillse a' bhroilleach17 sgrùdaidhean
- Ailse metastatach16 sgrùdaidhean
- Aillse (gach seòrsa)14 sgrùdaidhean
- Leukemia myeloid geur14 sgrùdaidhean
- Carcinoma Cealla Sgamach a' Chinn agus a' Mhuineil13 sgrùdaidhean
- Aillse sa bhlaire11 sgrùdadh
- Cancer Pancreatic11 sgrùdadh
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.